FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and may be used to suppress and/or delay mammalian cellular ageing. That is ensured by using a composition containing a non-genotoxic inducer of p53 (NGIP) by bringing the mammalian cells into the above composition. NGIP represents an Mdm-binding agent, or an Mdm-2 antagonist, or nutline, or nutline-3A, or a nutline analogue, or a combination thereof.
EFFECT: invention provides suppressing the cell ageing by cell transformation into the state of rest.
9 cl, 25 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSIENT CELLULAR REPROGRAMMING TO REVERSE CELL AGING | 2019 |
|
RU2801316C2 |
| METHODS AND COMPOSITIONS FOR DESTROYING AGING CELLS AND FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH AGING | 2015 |
|
RU2716256C2 |
| RAPAMYCIN TARGET INHIBITOR IN MAMMALIAN CELLS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 2019 |
|
RU2768583C2 |
| DRUG CONTAINING mTOR INHIBITOR FOR TREATMENT OR PREVENTION OF EYE SYMPTOMS, DISORDERS, OR DISEASES, AND ITS USE | 2018 |
|
RU2782613C2 |
| USE OF MYOSTATIN ANTAGONISTS, COMBINATION CONTAINING THEM AND THEIR USE | 2016 |
|
RU2781401C2 |
| TREATMENT OF TUMORS WITH A COMBINATION OF ONCOLYTIC ADENOVIRUS AND CDK4/6 INHIBITOR | 2019 |
|
RU2811278C2 |
| AGENT INDUCING CELL DEATH, CELL GROWTH INHIBITING AGENT, AND PHARMACEUTICAL COMPOSITION FOR TREATING DISEASE CAUSED BY ABNORMAL CELL GROWTH | 2015 |
|
RU2707746C2 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2616619C2 |
| APILIMOD FOR USE IN TREATING RENAL CANCER | 2015 |
|
RU2727802C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
